Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus brevis SBC8803 and Improved Atopic Dermatitis Symptoms

Research synthesisVery low evidenceSmall effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 review studies, all reported beneficial but predominantly small effects of Lactobacillus brevis SBC8803 on improving atopic dermatitis symptoms, though none provided statistically significant findings. The evidence is based solely on narrative or systematic reviews without original trial data, and no specific dose or population was consistently studied.

Caveats: All three studies are reviews without original clinical trial data, and none reported statistically significant findings. The evidence lacks direct experimental or clinical trials on Lactobacillus brevis SBC8803 specifically, with effects inferred from broader Lactobacillus research or microbiome analyses.

Generated May 10, 2026
3 of 3 papers
Back to top